You are here: Industry Insights > Financing

News List

UNITY Biotechnology, Inc. Completes $55 Million Series C Financing biospace
March 20, 2018
UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the closing of a $55 million Series C financing.
Arbor Biotechnologies Comes Out of Stealth Mode biospace
March 19, 2018
Arbor Biotechnologies, Inc., headquartered in Cambridge, Massachusetts, came out of stealth mode yesterday with a $15.6 million Series A financing round, which closed in June 2017.
IDEAYA Biosciences Raises $94 Million Crossover Series B Financing biospace
March 16, 2018
IDEAYA Biosciences, Inc., announced today the successful completion of a $94 million crossover Series B financing.
Forbion Leads $19 Million Series B Financing of Escalier Biosciences to Advance its Topical and Syst biospace
March 14, 2018
Forbion, today announced that it led the $19 million Series B financing of Escalier Biosciences BV, a privately held biopharmaceutical company based in Nijmegen, The Netherlands.
JW Therapeutics Closes $90 Million Series A Financing prnasia
March 09, 2018
JW Therapeutics today announced the completion of a $90 million Series A financing
Juno Therapeutics Spinout Raises $90M biospace
March 09, 2018
JW Therapeutics, headquartered in Shanghai, China, a clinical stage biopharma company founded by Juno Therapeutics and WuXi AppTec in 2016, closed a Series A financing worth $90 million.
CARsgen Completed $60 Million Pre-C Financing Framework Agreements biospace
March 05, 2018
CARsgen Therapeutics today announces it has entered into a Pre-C financing framework agreement with receiving $60M equity investment from existing and new investors.
One-Year Old Dracen Pharma Raises $40.5M, Hunts for Office and Lab Space With Plans to Hire biospace
January 31, 2018
Dracen Pharmaceuticals raised $40.5 million in equity financing from nine unidentified investors.
Filing Reveals Kendall Square's InVivo Therapeutics is Burning Through Cash Fast biospace
January 30, 2018
With an experimental spinal cord implant trial on hold for more than six months, Cambridge, Mass.-based InVivo Therapeutics has been rapidly burning through cash and may not have enough financing to continue operations for much longer.
APRINOIA Therapeutics Closes US$11 Million Series B Financing to Advance Its Tau PET Imaging Tracer prnasia
January 17, 2018
APRINOIA Therapeutics Inc., a clinical-stage neuroscience biotech company, focuses on tau, alpha-synuclein, and novel targets for neurodegenerative diseases, announces today the completion of its US$11.1 million Series B round.

Previous page 1 2 3 4 5 6 7 Next page